At CD ComputaBio, we are building an AI-empowered antibody therapeutics engine designed to discover and advance differentiated biologics for high-value disease areas. By integrating computational intelligence, antibody engineering, and translational insight, we aim to move promising programs from biological hypothesis to preclinical candidate with greater speed, precision, and strategic confidence. Our focus is not only to accelerate discovery, but to create the next generation of antibody therapeutics capable of addressing complex targets, difficult mechanisms, and significant unmet medical needs.
| Challenges | Our AI-Driven Solution | Impact |
| Long timelines & high cost | In silico antibody design & screening | ⬇ 50–70% time reduction |
| Low hit-to-lead success | Multi-parameter optimization | ⬆ higher success rate |
| Difficult targets | Epitope-focused AI design | Unlock "undruggable" targets |
| Late-stage failures | Early developability screening | Reduce downstream risk |
| Fragmented workflows | End-to-end AI platform | Streamlined pipeline |
At CD ComputaBio, we integrate advanced artificial intelligence with antibody engineering expertise to rapidly design, optimize, and advance next-generation antibody therapeutics. Our AbGenesis™ AI Platform enables partners to move from target identification to preclinical candidates faster, more efficiently, and with higher success rates.
The development of therapeutic antibodies has revolutionised modern medicine, enabling highly specific and effective treatments across oncology, autoimmune diseases, infectious diseases, and beyond. However, despite decades of innovation, traditional antibody discovery and engineering workflows remain time-consuming, costly, and uncertain, often requiring iterative experimental cycles with limited predictive power.
At CD ComputaBio, we are redefining antibody therapeutics through a fully integrated AI-driven antibody discovery and engineering platform. By combining advanced machine learning models, proprietary multi-modal biological datasets, and high-throughput experimental validation, we enable our partners to design, optimise, and develop next-generation antibodies with unprecedented speed, precision, and success rates.
We prioritize disease areas where biological complexity, target difficulty, and unmet clinical need create strong demand for more precise and differentiated antibody solutions. Our current strategic focus includes:
We pursue targets and antibody formats with the potential to overcome tumor heterogeneity, immune evasion, and resistance mechanisms, including opportunities for next-generation checkpoint biology, multispecific constructs, and differentiated tumor-targeting strategies.
We seek to design antibodies capable of modulating dysregulated immune networks with higher selectivity, improved safety logic, and clearer translational rationale, enabling more precise intervention without excessive systemic immunosuppression.
We explore antibody-based approaches against emerging and high-priority pathogens, with an emphasis on rapid hypothesis generation, target prioritization, and neutralizing or mechanism-driven biologic design.
AbGenesis™ is the integrated discovery and engineering platform that supports our antibody therapeutics strategy. Rather than functioning as a standalone software layer, it serves as the biological intelligence engine behind target assessment, antibody design, candidate prioritization, and iterative optimization.
Key areas of enablement include:
Our objective is not simply to generate more antibody candidates. It is to generate better therapeutic opportunities.
We believe future value in biologics comes from three capabilities:
By integrating multimodal biological signals, we can prioritize mechanisms and target hypotheses with stronger translational relevance.
AI-guided design and screening help compress early-stage iteration cycles, allowing promising programs to move forward with greater speed.
Through simultaneous optimization of affinity, specificity, developability, and mechanism logic, we aim to build candidates with a higher likelihood of standing out in competitive therapeutic landscapes.
Our core R&D pipeline is a testament to the transformative power of our AI-driven platform. We are rapidly advancing a portfolio of innovative antibody candidates, strategically focused on addressing the most challenging and high-impact disease areas where significant unmet medical needs persist. Our AI systematically guides our investment in therapeutic programs, prioritizing those with the highest probability of clinical success and profound patient benefit.
Guided by AI-derived insights into disease biology and global health priorities, we concentrate our efforts on therapeutic areas where our platform can make the most significant difference:
Our AI platform is uniquely positioned to discover novel immune checkpoints, identify new tumor-specific antigens, and engineer sophisticated multi-specific antibodies or ADCs that overcome tumor resistance mechanisms and enhance anti-tumor immunity.
Our AI rigorously analyzes complex inflammatory pathways and immune cell interactions to pinpoint critical cytokines, receptors, or cell types that drive pathology. We design highly specific, low-immunogenic antibodies that can precisely dampen aberrant immune responses without causing broad immunosuppression.
The rapid emergence of novel pathogens and antibiotic resistance underscores the urgent need for new anti-infective strategies. Our AI can rapidly analyze pathogen genomes, predict critical virulence factors, and design broad-spectrum or highly specific neutralizing antibodies against viruses, bacteria, or parasites.
A partner aimed to develop a bispecific antibody targeting:
Our platform enabled:
✓ Generated 80+ bispecific candidates in 2 weeks
✓ Identified top 8 candidates with balanced dual binding
✓ Improved stability by ~35% vs baseline designs
✓ Reduced design cycle time by >60%
A pharmaceutical company targeted a membrane protein with unknown structure, facing:
Limited structural data
Low success rate in traditional screening
Difficulty identifying functional epitopes
We applied:
AI-based epitope prediction using sequence + structural inference
Deep learning models for binding site identification
De novo antibody design targeting predicted epitopes
Virtual screening of candidate libraries
✓ Identified 5 high-confidence functional epitopes
✓ Generated 150+ candidate antibodies
✓ Top candidates achieved nanomolar binding affinity
✓ Increased hit rate by 3× vs traditional methods
We view partnership as a critical pathway for maximizing therapeutic impact. CD ComputaBio is open to strategic collaborations that accelerate the translation of advanced antibody programs into preclinical and clinical development. Depending on program fit and mutual objectives, collaboration models may include target-focused co-discovery, platform-enabled joint development, and broader strategic therapeutic partnerships. Contact us today to explore partnership opportunities or accelerate your antibody therapeutics program with our AI-powered platform.
